




RealRate

PHARMACEUTICAL 2023

Supernus Pharmaceuticals INC
Rank 219 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Supernus Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Supernus Pharmaceuticals INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 85% points. The greatest weakness of Supernus Pharmaceuticals INC is the variable Liabilities, Current, reducing the Economic Capital Ratio by 60% points.

The company's Economic Capital Ratio, given in the ranking table, is 274%, being 29% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	734,151
Cost of Goods Sold	0
Intangible Assets	819,482
Liabilities, Current	687,958
Liabilities, Non-Current	44,690
Other Assets	148,875
Other Compr. Net Income	-4,749
Other Expenses	169,373
Other Liabilities	83,656
Other Net Income	14,619
Other Revenues	667,238
Property and Equipment	0
Research and Development	74,552
Selling, General and Administrative Expense	377,221

Output Variable	Value in 1000 USD
Assets	1,702,508
Liabilities	816,304
Expenses	621,146
Revenues	667,238
Stockholders Equity	886,204
Net Income	60,711
Comprehensive Net Income	58,336
BaseVar	1,913,282
ECR before Limited Liability	158%
Economic Capital Ratio	274%